257 related articles for article (PubMed ID: 36361924)
21. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
22. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
23. Antiproliferative and tumor inhibitory studies of 2,3 disubstituted 4-thiazolidinone derivatives.
Sharath Kumar KS; Hanumappa A; Vetrivel M; Hegde M; Girish YR; Byregowda TR; Rao S; Raghavan SC; Rangappa KS
Bioorg Med Chem Lett; 2015 Sep; 25(17):3616-20. PubMed ID: 26152430
[TBL] [Abstract][Full Text] [Related]
24. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
[TBL] [Abstract][Full Text] [Related]
25. Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase.
Zeng F; Quan L; Yang G; Qi T; Zhang L; Li S; Li H; Zhu L; Xu X
Molecules; 2019 Jul; 24(15):. PubMed ID: 31370178
[TBL] [Abstract][Full Text] [Related]
26. Hybrid Molecules Containing Naphthoquinone and Quinolinedione Scaffolds as Antineoplastic Agents.
Mancini I; Vigna J; Sighel D; Defant A
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956896
[TBL] [Abstract][Full Text] [Related]
27. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency.
Shawky AM; Abourehab MAS; Abdalla AN; Gouda AM
Eur J Med Chem; 2020 Jan; 185():111780. PubMed ID: 31655429
[TBL] [Abstract][Full Text] [Related]
28. Thiazolidinedione: A Privileged Scaffold for the Development of Anticancer Agents.
Sun J; Chen YH; Liu HY; Hondo E; Zhou Y; Wu YF
Curr Top Med Chem; 2021; 21(28):2529-2545. PubMed ID: 34355685
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of thiazolidinone-pyrazole conjugates as anticancer and antimicrobial agents.
Bhat M; Poojary B; Kalal BS; Gurubasavaraja Swamy PM; Kabilan S; Kumar V; Shruthi N; Alias Anand SA; Pai VR
Future Med Chem; 2018 May; 10(9):1017-1036. PubMed ID: 29708431
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and In vitro Biological Activity of Some New 1,3- thiazolidine-4-one Derivatives as Chemotherapeutic Agents using Virtual Screening Strategies.
Nayak P; Kachroo M
Curr Comput Aided Drug Des; 2020; 16(6):757-771. PubMed ID: 31951175
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity.
Havrylyuk D; Zimenkovsky B; Karpenko O; Grellier P; Lesyk R
Eur J Med Chem; 2014 Oct; 85():245-54. PubMed ID: 25089808
[TBL] [Abstract][Full Text] [Related]
32. Structure based designing of thiazolidinone-pyrimidine derivatives as ERK2 inhibitors: Synthesis and in vitro evaluation.
Pathania S; Singh PK; Narang RK; Rawal RK
SAR QSAR Environ Res; 2021 Oct; 32(10):793-816. PubMed ID: 34583590
[TBL] [Abstract][Full Text] [Related]
33. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
34. A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis.
Rocha-Roa C; Molina D; Cardona N
Front Cell Infect Microbiol; 2018; 8():360. PubMed ID: 30386743
[No Abstract] [Full Text] [Related]
35. Advances in the development of hybrid anticancer drugs.
Fortin S; Bérubé G
Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents.
Ramshid PK; Jagadeeshan S; Krishnan A; Mathew M; Nair SA; Pillai MR
Med Chem; 2010 Sep; 6(5):306-12. PubMed ID: 21073435
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Anticancer Activity Evaluation of 5-[2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-thiazolidinones.
Buzun K; Kryshchyshyn-Dylevych A; Senkiv J; Roman O; Gzella A; Bielawski K; Bielawska A; Lesyk R
Molecules; 2021 May; 26(10):. PubMed ID: 34065476
[TBL] [Abstract][Full Text] [Related]
38. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating.
Bandyopadhyay D; Banik BK
Curr Med Chem; 2017; 24(41):4596-4626. PubMed ID: 28240166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
